1. Introduction {#s0005}
===============

Characterized by persistent sadness, pessimism, social withdrawal, low self-confidence, and compromised cognitive abilities, major depressive disorder (MDD) affects a large proportion of the population by significantly impairing their occupational, social and academic functioning ([@bb0025], [@bb0115], [@bb0155]). Changes in affective/emotional and cognitive processing accompanying MDD have been related to abnormal functioning of the insular, frontal (dlPFC, vlPFC, and mPFC), limbic (ACC, amygdala), hippocampal and thalamo-striatal (thalamus, globus pallidus, putamen, and caudate) brain regions ([@bb0020], [@bb0075], [@bb0195], [@bb0230], [@bb0250]). Furthermore, several neural networks, such as the default mode network (DMN), cognitive control network, as well as emotional regulation and saliency networks have been implicated in MDD neuropathology ([@bb0060], [@bb0235], [@bb0240], [@bb0280]). In addition to documenting illness biomarkers, recent advances in neuroimaging and brain stimulation methods have allowed for the development of new anti-depression treatments to complement traditional behavioral therapies and pharmacological approaches, further calling for the identification of reliable treatment biomarkers, for a review see ([@bb0160]).

More severe and treatment-resistant cases of MDD have been recently treated with vagus nerve stimulation (VNS), an invasive surgical procedure that involves implanting a stimulation device ([@bb0005], [@bb0100], [@bb0180], [@bb0185], [@bb0220]). Vagus nerve has been shown to have direct and indirect connections to the cortical-limbic-thalamic-striatal neural circuits relevant for depression, specifically influencing the dorsolateral prefrontal cortex, anterior cingulate, insula, and precuneus ([@bb0015], [@bb0135], [@bb0215], [@bb0225]). However, VNS being invasive and expensive to implement ([@bb0260]), transcutaneous VNS (tVNS) has been suggested as an alternative ([@bb0035]).

The method of tVNS targets the cutaneous receptive field of the auricular branch of the vagus nerve (ABVN) by applying an electrical stimulus to the left cymba conchae ([@bb0190]). As a non-invasive stimulation method tVNS has shown promising results for treating MDD ([@bb0090], [@bb0210]), however, optimizing the protocols could benefit from a clearer understanding of what specific changes in the brain contribute to the treatment success of tVNS. Neuroimaging could be instrumental for elucidating the mechanism of tVNS. Yet still little is known about the neural activations during tVNS in general, let alone specifically in depression. Several recent studies in healthy subjects showed that applying tVNS specifically affects brain stem structures (the ipsilateral nucleus tractus solitarii, bilateral spinal trigeminal nucleus, dorsal raphe, locus coeruleus), as well as cortical areas, including the insula, hippocampus, thalamus, nucleus accumbens, amygdala and paracentral gyrus ([@bb0030], [@bb0040], [@bb0050], [@bb0140], [@bb0150], [@bb0170]). The most reliably identified brain region in all studies has been the insula, although activation in the thalamus and deactivation in the hippocampus have also been consistently reported. The regions identified in these studies are potentially relevant for depression. However, these previous studies have not directly investigated the relationship between depression and tVNS. In a previous study, we found that longitudinal tVNS can alter resting state functional connectivity in the insula and the DMN ([@bb0045]). The brain response to tVNS during the treatment itself (compared with sham) and its association with the treatment-induced improvement, however, remain unknown ([@bb0040]).

In order to provide the crucial link showing the association between the activation during tVNS stimulation and the clinical outcome, in this study we set out to 1) reveal the patterns of fMRI signal changes during tVNS and sham treatment directly comparing the two to detect the specific effect of tVNS and understand the basis for the therapeutic effect of sham tVNS; 2) explore neuroimaging biomarkers that might predict the success of tVNS longitudinal treatment already during the first treatment session. We hypothesized that increased activation in the insula and decreased activation in the DMN, as suggested by resting stage changes in our previous study based on the same sample would show differential activation during tVNS compared with sham and predict longitudinal treatment success.

2. Methods {#s0010}
==========

2.1. Subjects {#s0015}
-------------

Forty-nine subjects MDD patients naïve to tVNS were enrolled in this single blinded clinical trial from three participating hospitals. The inclusion criteria were 1) meeting ICD-10 diagnosis (2 typical and 2--3 other core symptoms); 2) depressive symptoms exhibited for at least 2 months but \< 2 years; 3) aged between 16 and 70; 4) anti-depressive and other psychiatric medication free for 2 weeks before the intervention; 5) education above junior high school and ability to understand the scales. Subjects with very severe depression and suicidal thoughts, drug addiction, or other severe health problems, such as heart disease, kidney failure were excluded from the study. All subjects provided informed consent before the start of the study. Only subjects that underwent fMRI scanning during the first treatment session were included in the current analysis, resulting in the total of 38 subjects. [Table 1](#t0005){ref-type="table"} shows the demographic characteristics of the subject cohort.Table 1Demographic information. HAM-D, Hamilton Depression Scale; SDS, Self-Rating Depression Scale; tVNS, transcutaneous vagus nerve stimulation.Table 1VariabletVNSSham*p*-valueN (male)17 (5)21 (7)0.79 (Chi-square test, 2-tailed)Age mean (SE)40.35 (3.2)40.38 (2.4)0.99 (2-sample *t*-test, 2-tailed)SDS (pre) score mean (SE)70.35 (2.0)67.57(1.8)0.31 (2-sample *t*-test, 2-tailed)HAM-D (pre) score mean (SE)30.47 (1.0)28.52 (0.9)0.18 (2-sample *t*-test, 2-tailed)

2.2. Intervention {#s0020}
-----------------

All treatments were applied with an ear vagus nerve stimulator developed through the cooperation of the Institute of Acupuncture and Moxibustion, China Academy to Chinese Medicine Science (Beijing, China) and Suzhou Medical Appliance Factory (Jiangsu Province, China), featuring custom-designed ear clips (electrodes) ([@bb0105], [@bb0200], [@bb0205]).

Participants were trained to apply tVNS or sham and subsequently self-administered all treatments at home. Patients were instructed to sit or lie on their side, disinfect the stimulation points and attach ear clips on the stimulation sites. Stimulation parameters were as follows: a 20 Hz continuous sinusoidal wave (wave width of 0.2 ms); stimulation intensity increased gradually (starting from 0) to the highest point that the patients could tolerate without it being painful (typically between 4 and 6 mA); stimulation lasted 30 min and was applied twice a day, at least 5 days a week for 4 weeks. Patients were also instructed to daily complete a patient diary booklet to describe any side effects of treatment. All procedures for the tVNS and sham treatment groups were identical except the location of the stimulation. The points for the tVNS were located in the auricular concha area known to have vagus nerve branch distributions; the stimulation points for the sham treatment were located at the superior scapha (outer ear margin midpoint) devoid of vagus nerve distribution ([@bb0190]) ([Fig. 1](#f0005){ref-type="fig"}). To avoid the noise evoked by the electrical current of tVNS, the connecting line between the stimulator and the ear was electromagnetically shielded. A round tin electrode, about 5 mm in diameter, was installed at the distant end of the line. The electrodes were fixed by tape during the fMRI scan ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Locations for the tVNS and sham stimulation.Fig. 1

2.3. Behavioral data analysis {#s0025}
-----------------------------

All dependent variables were measured at week 0 and week 4. The primary measurement was the 24-item Hamilton Depression Rating Scale (HAM-D), secondary measurements included the Hamilton Anxiety Rating Scale (HAM-A), Self-Rating Anxiety Scale (SAS), and Self-Rating Depression Scale (SDS). All behavioral results of the trial were analyzed and reported elsewhere ([@bb0045]), we here only focus on the HAM-D score relationship to the brain activation during the first fMRI session. To assess the effect tVNS and sham on MDD in the sample used here, we performed a repeated measures ANOVA with Group (tVNS vs. sham) and Treatment time point (pre vs. post) on subjects\' HAM-D scores, followed by planned comparisons for pre- and post- results within and between each group.

2.4. Imaging data acquisition and analysis {#s0030}
------------------------------------------

Brain imaging was performed with a 1.5 Tesla GE Signa MRI system (GE Healthcare, Buckinghamshire, United Kingdom) equipped with the standard two-channel birdcage head coil. T1-weighted high-resolution structural images were acquired with the three-dimensional fast spoiled gradient-echo sequence (matrix 192 × 256, field of view \[FOV\] 200 mm, flip angle 15°, slice thickness 1.4 mm). T2-weighted functional images encompassing the whole brain were acquired with the gradient echo echo-planar imaging sequence (echo time 30 ms, repetition time 2500 ms, matrix 64 × 64, FOV 240 mm, flip angle 90°, slice thickness 3.0 mm, gap 0.5 mm, 41 slices, paralleled by anterior commissure-posterior commissure line). Task functional scans consisted of two 6-min tVNS or sham stimulation sessions performed in the scanner ([Fig. 2](#f0010){ref-type="fig"}). Image collection was preceded by four dummy scans to allow for equilibration of the MRI signal. Two 6-min resting state fMRI scans were applied while the subjects were required to keep their eyes closed.Fig. 2Stimulation protocol. Each session took 6 min to complete. Two stimulation sessions were recorded per subject. S: stimulation.Fig. 2

Preprocessing and statistical analyses were performed using SPM12 software (Wellcome Department of Cognitive Neurology, London, UK). Preprocessing included realignment, normalization to MNI stereotactic space, and spatial smoothing with a 6 mm Gaussian kernel. For each subject, a GLM (general linear model) design matrix was calculated, including all stimulation events (2 sessions of 3 stimulations lasting 30-second each). In addition, head motion analysis was performed using the artifact detection toolbox (ART) (<https://www.nitrc.org/projects/artifact_detect/>). Time points were marked as outliers if global signal exceeded three standard deviations of the mean and if movement exceeded 0.5 mm of scan-to-scan deviation. As head motion can differ from subject to subject ([@bb9000]), we included ART-identified movement artifacts as covariates in first-level analyses.

After computing the contrast between stimulation 'on' and implicit baseline for each subject, we performed one-sample *t*-tests to identify activations and deactivations during stimulation vs. baseline separately for tVNS and sham groups. Finally, we directly compared stimulation-induced activations in the two groups by using a 2-sample *t*-test. A threshold of voxel-wise *p* \< 0.001, cluster-corrected at *p* \< 0.05 (FWE) was used for the one-sample *t*-tests. A threshold of voxel-wise *p* \< 0.05 (FWE) after small volume correction (svc) was set for the group comparison with the initial thresholding of *p* \< 0.005. Cortical brain regions previously implicated in tVNS and depression were used as independent regions of interest (ROIs) for svc. These included the bilateral anterior insula, precuneus, thalamus and hippocampus ([@bb0145]). All regions of interest were anatomically defined using the Harvard-Oxford Atlas-based parcellation previously reported in ([@bb0070]). All coordinates were reported in MNI space, as used in SPM.

In order to check whether there was an association between insular activity during the first tVNS session and HAM-D improvement following the real tVNS treatment, we have performed a partial correlation between the post-treatment HAM-D scores (adjusting for age, gender and pre-treatment HAM-D scores) and the signal extracted from the insula (a sphere with a 6 mm radius around the peak coordinate of the small volume-corrected contrast between tVNS and sham).

3. Results {#s0035}
==========

3.1. Sample characteristics {#s0040}
---------------------------

Data from 38 subjects were included in the current analysis (tVNS *N* = 17; sham *N* = 21). Note that this was part of the same tVNS research study reported in ([@bb0045]). The current sample is, however, slightly different, as not all tVNS subjects from the previously reported cohort underwent fMRI scanning during the first session and more sham subjects had fMRI data during the stimulation available.

3.2. Behavioral data results {#s0045}
----------------------------

The results of the repeated measures ANOVA on HAM-D scores with the factors Group and Treatment time point showed a significant main effect of Treatment time point (F~(1,36)~ = 78.02, *p* \< 0.01), suggesting that in both treatment groups there was a decrease in HAM-D scores (tVNS: t~(16)~ = 8.06, *p* \< 0.01; sham: t~(20)~ = 4.29, *p* \< 0.01)) ([Fig. 3](#f0015){ref-type="fig"}A). Importantly, there was also a significant interaction between Group and Treatment time point (F~(1.36)~ = 15.45, *p* \< 0.01), suggesting that there was greater improvement in the tVNS group, compared with the sham group. Planned comparisons between the groups showed that there was a significant difference between the groups post-treatment (t~(36)~ = 3.44, *p* \< 0.01) but not pre-treatment (t~(36)~ = 1.37, *p* = 0.18). The decrease in HAM-D score following treatment constituted 42.45% in the tVNS and 17.15% in the sham group.Fig. 3Bar graph demonstrating HAM-D scores pre- and post-treatment by group (tVNS vs. sham).Fig. 3

3.3. Imaging data results {#s0050}
-------------------------

First we investigated patterns of activation and deactivation during tVNS and sham treatment; they are reported in [Table 2](#t0010){ref-type="table"}. In the tVNS group, the results showed increased activation in the left insula and bilateral cerebellum and a deactivation in the DMN (MPFC and precuneus). In the sham group, there was a significant activation in the right inferior frontal gyrus, as well as a deactivation in the DMN (MPFC, posterior cingulate and precuneus) and the left hippocampus.Table 2One-sample *t*-tests, whole-brain *p* \< 0.001, k = 20, cluster-corrected FWE-corr. *p* \< 0.05.Table 2Brain regionHemisphereMNI coordinateskTZPeak p(unc)Cluster p(FWE-corr)xyz**tVNS treatment (one-sample*****t*****-test)***Activation*Cerebelum Crus1L− 27− 73− 34969.115.33\< 0.001\< 0.001Cerebelum Crus1R36− 67− 281327.975\< 0.001\< 0.001Operculum/Insula/Precentral gyrusL− 57− 18466.44.45\< 0.0010.003  *Deactivation*Medial Frontal GyrusR1244− 10396.334.42\< 0.0010.008PrecuneusR9− 58443853.83\< 0.0010.009  **Sham treatment (one-sample*****t*****-test)***Activation*Middle Frontal/Inferior Frontal GyrusR512326687.985.29\< 0.0010.001Inferior Frontal GyrusR54115375.254.12\< 0.0010.023  *Deactivation*Posterior Cingulate/CalcarineR15− 5511487.164.99\< 0.0010.006Medial Frontal GyrusR344− 101405.974.47\< 0.001\< 0.001PrecuneusR12− 5259556.124.54\< 0.0010.003HippocampusL− 12− 7− 22315.034\< 0.0010.048

Direct comparison of the two stimulation groups revealed more activation in the tVNS, compared with the sham group, in the left anterior insula (peak MNI coordinate \[− 30, 8, 8\]), small-volume corrected at FWE *p* \< 0.05 ([Fig. 4](#f0020){ref-type="fig"}). No significant difference was observed for the opposite contrast.Fig. 4Results of a 2-sample *t*-test, tVNS \> sham, whole-brain *p* = 0.005 (SVC for multiple comparisons).Fig. 4

We further investigated the association between the insula activity during first stimulation session and longitudinal treatment outcome (post-treatment HAM-D scores adjusted for age, gender and pre-treatment HAM-D scores) in real and sham tVNS groups separately. The partial correlation between the insula (6-mm radius sphere at MNI \[− 30, 8, 8\]) and treatment outcome (HAM-D score after 4 weeks) was significant in the real tVNS group (r~(17)~ = − 0.65, *p* = 0.01), suggesting that the more activated the insula was during the first stimulation treatment the lower HAM-D score at the end of 4 weeks of treatment was observed ([Fig. 5](#f0025){ref-type="fig"}). There was no significant association in the sham group (*p* = 0.6), suggesting that the activation of the insula does not generally reflect the state of depression but is associated with treatment efficacy in the tVNS group.Fig. 5Scatter plot showing a significant negative correlation between HAM-D scores at 4 weeks and activation in the left dorsal anterior insula during the first treatment session (values extracted from a sphere with 6 mm radius around the peak coordinate (− 30, 8, 8)) in the tVNS group, suggesting that greater activation of the insula during treatment is associated with better treatment outcome. The lines represent least squares linear fits (darker line for the tVNS group correlation).No association was observed in the sham group.Fig. 5

4. Discussion {#s0055}
=============

The goal of the study was twofold: 1) to reveal patterns of fMRI activation during tVNS and sham treatment in depressed patients and directly compare them to detect the specific effect of tVNS on MDD-related neuropathology; 2) to identify neuroimaging biomarkers that could predict the success of tVNS longitudinal treatment already during the first treatment session. The results indicate that the activation level in the left anterior insula might be enhanced by tVNS compared with sham. Specifically for the real tVNS insula activation was associated with the longitudinal treatment outcome and could in principle be used to predict the results of a 4-week treatment already at the first session. Other brain regions, including the cerebellum appear to be modulated more by tVNS than sham, while the overall HAM-D score improvement observed in both tVNS and sham can be related to the modulation of parts of the DMN (MFPC, precuneus) and hippocampus previously shown to influence depression symptoms.

4.1. Left anterior insula is activated more by tVNS than sham and predicts treatment outcome {#s0060}
--------------------------------------------------------------------------------------------

Previous neuroimaging studies investigating the effect of tVNS in healthy subjects have consistently reported an increase in the activation of the anterior insula during the stimulation ([@bb0050], [@bb0140], [@bb0145]). In fact in the study by Kraus et al. ([@bb0145]) insula was the only region that was positively activated regardless of whether anterior or posterior part of the left auditory canal was stimulated, while in most other cortical areas changes were in the opposite direction between the stimulation sites.

Being a hub for emotional and saliency processing, insula is a key region in MDD neuropathology previously shown to be involved in both clinical ([@bb0265]) and subclinical depression ([@bb0110]). Previous studies found abnormal insula task activation ([@bb0065]) and decreased regional homogeneity in resting state functional MRI in the right insula in participants with MDD ([@bb0165]). A number of studies showed MDD-related reduction in insular volume ([@bb0265]), specifically in the left anterior insula ([@bb0010], [@bb0080], [@bb0255], [@bb0270]). Crucially these studies demonstrated correlations between the left anterior insula volume and depressive and psychotic symptoms. Furthermore, anterior insula, albeit right, has been previously proposed as a biomarker for the treatment selection for MDD. Specifically, fluorodeoxyglucose (FDG) positron emission tomography (PET) signature in the insula was found to discriminate between cognitive behavioral therapy and antidepressants responders ([@bb0175]).

Our behavioral results show that tVNS significantly decreased HAM-D scores compared to the pre-treatment level and also compared with the sham treatment results. In addition, fMRI results further confirm that the left anterior insula was significantly activated during the tVNS treatment but not sham. Together these findings suggest that the effect of tVNS treatment might be primarily achieved through the modulation of the left anterior insula activity. This result is further corroborated by our previous resting state connectivity study showing changes in insula-DMN connectivity for pre-post tVNS compared to sham ([@bb0045]). Crucially, this new finding of the association between the insula activation during tVNS and depression improvement was obtained during the very first stimulation session, suggesting that it might be useful for an early prediction of longitudinal tVNS treatment outcome ([@bb0160], [@bb0175]), e.g., if the insula activation is observed patients are likely to benefit from tVNS treatment, if the insula is not active during the stimulation, the treatment is not likely to be effective. While the results of this task fMRI and our previous resting state fMRI studies agree well, they are part of the same trial involving the same cohort (although note that the number of subjects in the two studies is not exactly the same, since our previous study included only subjects with resting state fMRI data both at baseline and post-treatment). Further replication in independent samples is necessary to confirm the role of insula in tVNS effect on depression and the association between the brain activation during stimulation and long-term changes in the resting state.

Although not revealed by the direct comparison between sham and tVNS, bilateral cerebellum was significantly activated during tVNS but not during sham, as suggested by the one-sample *t*-tests ([Table 2](#t0010){ref-type="table"}). The cerebellum ([@bb0130]) has been shown to be dysregulated in MDD. Often the cerebellum was implicated in MDD together with the insula, e.g. regional homogeneity decreases in the insula and cerebellum ([@bb0165]). In addition, cerebellar modulation has been reported for VNS, e.g., ([@bb0095]). The role of the cerebellum in tVNS effect for depression should be further explored.

We also were not able to observe any significant differences in the activation of the nucleus of the solitary tract (NTS) that is expected in verum tVNS ([@bb0050], [@bb0145]). Most previous studies reporting this activation optimized their fMRI acquisition sequences (e.g., focusing on the brain stem), pre-processing (e.g., omitting the smoothing step), or statistical analysis (e.g., using ROI analysis vs. whole-brain analysis) to have the power and sensitivity to observe the activity in this region. We here focused on the cortical biomarkers of tVNS using standard fMRI acquisition, pre-processing and statistical analysis, that could facilitate assessing treatment success in a clinical setting. Insula activation similar to our report here has also been found in a previous study that showed differential NTS activation ([@bb0145]), suggesting that there might be co-activation of the two during tVNS. Insula and NTS are known to have direct and indirect anatomical connections ([@bb0085], [@bb0120], [@bb0245]), which could be particularly important for the application of tVNS in depression. While the absence of observed NTS activation may present a major limitation in our study, it could be related to a general difficulty of observing NTS activity with conventional fMRI, calling for a more robust biomarker for manipulation success.

4.2. Sham tVNS brain activation and clinical outcome {#s0065}
----------------------------------------------------

While a significant difference in both behavioral and imaging results has been observed between tVNS and sham treatment, there was a significant therapeutic effect of sham tVNS, as well as significant activation and deactivation of MDD-related brain regions during the stimulation. Specifically, 17% improvement from the baseline ('post' minus 'pre' divided by 'pre') was observed in the sham condition (compared to 42% in the tVNS condition). The right inferior frontal gyrus has not been related to either depression or tVNS, so its increased activation during sham could be epiphenomenal sensory activation. However, during the sham stimulation, deactivation in the key regions of the DMN were observed -- MPFC, precuneus, posterior cingulate, similar to the deactivations seen during tVNS ([Table 2](#t0010){ref-type="table"}). The involvement of the DMN in MDD and its stimulation by the tVNS are discussed in more detail in ([@bb0045]). In addition, a deactivation in the hippocampus, previously reported in tVNS imaging studies ([@bb0030], [@bb0050], [@bb0140]), appeared in the sham condition. This suggests that there might be some effect of sham stimulation in the regions relevant for the clinical outcome. It should be noted that previous studies used a different sham stimulation site, namely sham stimulation electrodes were placed in the center of the left earlobe ([@bb0050], [@bb0140], [@bb0145]), known to be free of vagal innervation ([@bb0190]). We here used the outer ear margin midpoint for stimulation that has also been shown to be 100% innervated by the great auricular nerve, like the lobule of auricle ([@bb0190]). The main reason we chose this location was that it is predominantly controlled by the minor occipitalis nerve of the cervical plexus, and the tissue layer at this location is similar to the location where the tVNS was applied.

One explanation for the behavioral improvement following the sham treatment could be a placebo response. The large placebo effect observed in our study is in line with findings from a previous clinical trial testing the efficacy of antidepressants ([@bb0125]). A strong placebo expectation would be associated with both tVNS and sham to the same extent and potentially reflected in the activation of the same brain regions for tVNS and sham. Consistent with that both tVNS and sham conditions produced a decrease in DMN regions. The insula activation was observed only in tVNS, potentially corresponding to the specific treatment effect without the placebo confound. At the same time the brain regions that showed deactivation in the sham condition, such as the posterior cingulate, MPFC, precuneus and hippocampus are not key regions associated with a typical placebo response ([@bb0055], [@bb0275]). It is therefore possible that the significant decrease in the DMN and the hippocampus induced by the sham stimulation (as well as tVNS) was more specific to depression.

At the same time, qualitative difference between the depressive symptoms improvement between tVNS and sham could be observed, suggesting that despite some positive effect of the sham stimulation, it is significantly smaller than the therapeutic effect of proper tVNS. In addition, post-treatment HAM-D scores differed between the groups in terms of severity levels ([@bb0285]). At the end of the treatment depression severity in the tVNS group was reduced to the 'mild' level (with the score 17 ± 1) and in the sham group it remained at the 'moderate' level (with the score 23 ± 1). This qualitative comparison suggests that the distinction between tVNS and sham treatment in our study is clinically meaningful and goes beyond numerical significance, further emphasizing that key MDD neural network was only affected by tVNS but not sham.

5. Summary {#s0070}
==========

This study is the first to investigate the neural effects of tVNS during the stimulation in a sample of depressed patients. We report that tVNS is successful for depression treatment and specifically targets the left anterior insula compared to sham. The activation of the anterior insula by the tVNS stimulation during the first treatment session predicts the outcome of the longitudinal tVNS treatment. Based on the results of our study, we recommend the use of fMRI during tVNS to monitor insula activity during treatment to ensure its efficacy and appropriateness as MDD treatment. Future studies need to further investigate the use of anterior insula as a cortical biomarker for tVNS and adapt the paradigm to allow for the prediction of success at a single subject level.
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